Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 460-469

  Kuerer, Henry M ^a   Newman, Lisa A ^a   Smith, Terry L ^a   Ames, Fred C ^a   Hunt, Kelly K ^a   Dhingra, Kapil ^a   Theriault, Richard L ^a   Singh, Gurpreet ^a   Binkley, Susan M ^a   Sneige, Nour ^a   Buchholz, Thomas A ^a   Ross, Merrick I ^a   McNeese, Marsha D ^a   Buzdar, Aman U ^a   Hortobagyi, Gabriel N ^a   Singletary, S Eva ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

EID: 0033050164     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.460     Document Type: Article

References (40)

1. Delena M, Zucali R, Viganotti G, et al: Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1:53-59, 1978
2. Hortobagyi GN, Blumenschein GR, Spanos W, et al: Multimodal treatment of locoregionally advanced breast cancer. Cancer 51:763-768, 1983
3. Lippman ME, Sorace RA, Bagley CS, et al: Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1:156-159, 1986
4. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer 5:645-652, 1994
5. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
6. Feldman DL, Hortobagyi GN, Buzdar AU, et al: Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578-2581, 1986
7. American Joint Committee on Cancer: Manual for Staging of Cancer (ed 6). Philadelphia, PA, Lippincott, 1998
8. Cox DR, Snell EJ. Analysis of Binary Data (ed 2). New York, NY, Chapman and Hall, 1989
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 185:1457-1481, 1958
10. Mantel N: Evaluation of survival data and two row rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
11. Schwartz GF, Birchansky CA, Komarnicky LT, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1994
12. Powles TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
13. Brain E, Garrino C, Misset JL, et al: Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 79:1360-1367, 1997
14. Morrell LE, Lee YJ, Hurley J, et al: A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 82:503-511, 1998
15. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
16. McCready DR, Hortobagyi GN, Kau SW, et al: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124:21-25, 1985
17. Schaake-Koning C, Van der Linden EH, Hart G, et al: Adjuvant chemo-and hormonal therapy in locally advanced breast cancer: A randomized clinical study. Int J Radiat Oncol Biol Phys 11:1759-1763, 1985
18. Cunningham JD, Weiss SE, Ahmed S, et al: The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest 16:80-86, 1998
19. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel, a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant breast cancer. J Clin Oncol 13:2886-2894, 1995
20. Seidman AD, Reichman BS, Crown JP, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
21. Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516, 1988
22. Valagussa P, Zambetti M, Bonadonna G, et al: Prognostic factors in locally advanced breast cancer: Long-term results following primary chemotherapy. Breast Cancer Res Treat 15:137-147, 1990
23. Ellis P, Smith I, Ashley S, et al: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16:107-114, 1998
24. Touboul E, Lefranc JP, Blondon J, et al: Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiother Oncol 25:167-175, 1992
25. Abu-Farsakh H, Sneige N, Atkinson EN, et al: Pathologic predictors of tumor response to preoperative chemotherapy in locally advanced breast carcinoma. Breast J 1:96-101, 1995
26. Berard CW, Greene MH, Jaffe ES, et al: A multidisciplinary approach to non-Hodgkin's lymphomas. Ann Intern Med 94:218-235, 1981
27. Lippman ME, Allegra JC, Thompson EB, et al: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
28. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
29. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2:347-354, 1991
30. Polychemotherapy for early breast cancer: An overview of the randomised trials: Early Breast Cancer Trialists' Collaborative Group. Lancet 352:930-942, 1998
31. Fisher ER, Sass R, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project: Correlation with concordant and discordant estrogen and progesterone receptors. Cancer 59:1554-1559, 1987
32. Dabbs DJ: Ductal carcinoma of the breast: Nuclear grade as a predictor of S-phase fraction. Hum Pathol 24:652-656, 1993
33. Remvikos Y, Beuzeboc P, Zajdela A, et al: Pretreatment proliferative activity of breast cancer correlates with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81:1383-1387, 1989
34. Hyytinen E, Visakorpi T, Kallioniemi A, et al: Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry 16:93-99, 1994
35. Kallioniemi OP, Kallioniemi A, Piper J, et al: Optimizing comparitive genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosom Cancer 10:231-243, 1994
36. Teixeira MR, Pandis N, Bardi G, et al: Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res 56:855-859, 1996
37. Kuukasjärvi T, Karhu R, Tanner M, et al: Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57:1597-1604, 1997
38. Resnick JM, Sneige N, Kemp BL, et al: p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma. Breast Dis 8:149-158, 1995
39. Chevillard S, Pouillart P, Beldjord C, et al: Sequential assessment of the multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292-300, 1996
40. Makris A, Powles TJ, Dowsett M, et al: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3:593-600, 1997